Jun 21,2024

New MiniMed 780G system data demonstrates ability to address persistent blood sugar challenges for people with type 1 diabetes

Medtronic plc presented new data at the American Diabetes Association's 84th Scientific Sessions highlighting the benefits of its MiniMed 780G system. The system, equipped with an advanced algorithm providing autocorrections every 5 minutes, showed significant improvements in managing hyperglycemia and reducing nighttime disruptions for people with type 1 diabetes. A retrospective analysis of real-world data (n=6026) demonstrated a substantial decrease in dawn phenomenon rates from 12.2% to 4.5% when users transitioned from the MiniMed 770G to the MiniMed 780G system. Time in Range also increased significantly, from 87.7% to 91.4% from midnight to 6 a.m. The next iteration of the MiniMed™ 780G system, combined with the Simplera Sync™ sensor, showed promising results in clinical outcome metrics like Time in Range and Time Above Range compared to other delivery methods.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 20,2024

Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S. along with iPhone app

Insulet has launched its Omnipod 5 system with Dexcom G7 CGM across the United States, marking the first FDA-cleared tubeless automated insulin delivery system that communicates with a CGM. This system proactively manages blood sugar levels by adjusting insulin doses to correct highs and prevent lows. Insulet also introduced a limited release of the Omnipod 5 App for iPhone, enhancing user control and convenience. The company expanded Omnipod 5 availability in Europe, including a launch in France with compatibility for Dexcom G6 and Abbott FreeStyle Libre 2 Plus sensors, aiming to broaden access to advanced diabetes management solutions globally.

PRODUCT

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 13,2024

GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR

Glucotrack has announced the successful completion of a 60-day long-term preclinical study for its epidural continuous glucose monitoring sensor. The study demonstrated the sensor's ability to accurately monitor glucose levels in the epidural space, aligning closely with readings from traditional blood glucose monitors and subcutaneous CGMs. Throughout the study, no abnormal clinical signs or tissue reactions were observed, affirming the safety and reliability of the implanted sensor. Glucotrack plans to further develop this technology aimed at simplifying disease management for patients with painful diabetic neuropathy, potentially integrating it with existing treatments in the future.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 20,2024

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS

Glucotrack, a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it has appointed Andy Balo to its Board of Directors, effective immediately. Mr. Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002 he joined Dexcom as part of the original executive team where he remained for the next 22 years playing a critical role in shaping the company’s future. During his tenure, he was responsible for numerous glucose monitoring regulatory submissions and clinical trials worldwide and coordinated quality activities across multiple manufacturing facilities. In March 2024, Mr. Balo retired from Dexcom as Executive Vice President of Clinical, Global Access, and Medical Affairs. 

View Analyst & Ambassador Comments
Go to original news
Jun 20,2024 TOP STORY

Economic Savings Model for Omada’s Cardiometabolic Programs

The study funded by Omada Health and conducted by Madison Noble, MPH, and Fang Chen, PhD, aimed to model the economic and health benefits of participating in virtual-first care (V1C) programs for cardiometabolic conditions. Using a microsimulation approach, the study focused on four types of programs: prevention, hypertension, diabetes, and diabetes plus hypertension. Participants showed sustained improvements in weight loss, hemoglobin A1c (HbA1c), and blood pressure (BP) levels, which were estimated to reduce disease onset by 2% to 10% over five years following enrollment. The study projected significant gross savings in healthcare expenditures. After one year, estimated savings ranged from $892 to $1342 per participant, with cumulative savings of $2963 to $4346 after three years, and $5221 to $7756 after five years.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 20,2024

Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes

Dexcom is showcasing its advancements in continuous glucose monitoring (CGM) at the ADA's 84th Scientific Sessions in Orlando. They highlight significant data demonstrating the benefits of Dexcom CGM for Type 2 diabetes and prediabetes, including improved A1C and lifestyle impacts. Dexcom emphasizes its leadership in CGM connectivity, announcing the integration of Dexcom G7 with the Omnipod 5 Automated Insulin Delivery System and various insulin pumps. They also underscore their commitment to innovation with updates to Dexcom G7, including Direct to Apple Watch connectivity and enhanced Bluetooth features.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 25,2024

Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1

DarioHealth Corp. announced new research showing that its digital platform supports sustained healthy behavior changes over 12 months for members taking GLP-1 medications for Type 2 diabetes. This retrospective study analyzed the data of 7,240 individuals with Type 2 diabetes using Dario to help manage their condition without the help of insulin for at least six months. The data, presented at the 84th Annual American Diabetes Association (ADA) Scientific Sessions, revealed that Dario's personalized approach led to significant improvements in blood glucose levels and increased healthy lifestyle activities. Additionally, 31% of Dario members achieved results consistent with diabetes remission, maintaining normal blood glucose levels without diabetic medications.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Jun 18,2024

CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management

CeQur has received FDA clearance for its CeQur Simplicity™ wearable insulin delivery device to extend wear duration from 3 to 4 days. This advancement aims to simplify diabetes management by reducing the number of injections needed for mealtime insulin. The device is designed to replace up to 12 injections per patch, offering discretion and convenience. Supported by data showing low adherence to A1C goals among people with Type 2 Diabetes using multiple daily injections, CeQur Simplicity's extended wear time intends to enhance dosing adherence and improve quality of life.

REGULATORY FDA

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 27,2024

Aeroflow Health Launches Personalized Nutrition Services, Harnessing the Power of Food to Improve Health & Wellness Outcomes

Aeroflow Health has launched Aeroflow Nutrition Services, a telehealth initiative offering personalized and group-based sessions with qualified dietitians. Initially focusing on patients with type 2 diabetes, these services aim to simplify nutrition counseling and leverage food as a tool to manage diabetes effectively. The program is accessible virtually, covered by insurance with minimal out-of-pocket costs for most patients, positioning it as a preventative care benefit. Aeroflow Nutrition Services aligns with the Food Is Medicine movement, emphasizing nutrition's critical role in disease prevention and management.

PRODUCT

#telehealth

View Analyst & Ambassador Comments
Go to original news
Jun 10,2024

ABBOTT RECEIVES U.S. FDA CLEARANCE FOR TWO NEW OVER-THE-COUNTER CONTINUOUS GLUCOSE MONITORING SYSTEMS

Abbott has received FDA clearance for two new over-the-counter continuous glucose monitoring (CGM) systems: Lingo and Libre Rio. Lingo is designed for consumers seeking to improve overall health and wellness, providing personalized insights and coaching based on continuous glucose data. It targets metabolic health improvement by tracking glucose levels and lifestyle factors. Libre Rio, Abbott's first OTC CGM for adults with Type 2 diabetes not using insulin, focuses on managing diabetes through lifestyle modifications. Both systems utilize FreeStyle Libre technology and aim to enhance health outcomes by empowering users with actionable glucose data.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES